Literature DB >> 31144731

Interstitial cystitis, bladder pain syndrome, hypersensitive bladder, and interstitial cystitis/bladder pain syndrome - clarification of definitions and relationships.

Yukio Homma1.   

Abstract

Interstitial cystitis and interstitial cystitis-related conditions such as bladder pain syndrome and hypersensitive bladder have a similar symptomatic profile but probably different etiologies. A meaningful classification of these diseases/conditions is mandatory for clinical and investigational progress. The condition with Hunner lesions (Hunner type interstitial cystitis) is distinct from other categories in terms of histopathology, gene expression, and clinical management. Classification should clearly differentiate the presence or absence of Hunner lesions. The term covering patients as a whole should contain interstitial cystitis, since interstitial cystitis is historically a well-known name and used for insurance reimbursement. The proposed taxonomy features an umbrella term (interstitial cystitis/bladder pain syndrome) and two subgroups, Hunner type interstitial cystitis (with Hunner lesions) and bladder pain syndrome (without Hunner lesions). Interstitial cystitis/bladder pain syndrome is convenient for initial management, and subgroups can categorize the patients for specific management. The characteristic symptom profile is to be collectively termed as hypersensitive bladder symptoms. Editorial material and organization
© 2019 The Japanese Urological Association. Copyright of individual abstracts remains with the authors.

Entities:  

Year:  2019        PMID: 31144731     DOI: 10.1111/iju.13970

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  5 in total

1.  Immunohistochemistry as a paramount tool in research of normal urothelium, bladder cancer and bladder pain syndrome.

Authors:  Daša Zupančič; Rok Romih
Journal:  Eur J Histochem       Date:  2021-03-24       Impact factor: 3.188

2.  Activation of GPR18 by Resolvin D2 Relieves Pain and Improves Bladder Function in Cyclophosphamide-Induced Cystitis Through Inhibiting TRPV1.

Authors:  Qudong Lu; Yang Yang; Hengshuai Zhang; Cheng Chen; Jiang Zhao; Zhenxing Yang; Yi Fan; Longkun Li; Huan Feng; Jingzhen Zhu; Shanhong Yi
Journal:  Drug Des Devel Ther       Date:  2021-11-15       Impact factor: 4.162

3.  Predictive Factors for a Satisfactory Treatment Outcome with Intravesical Botulinum Toxin A Injection in Patients with Interstitial Cystitis/Bladder Pain Syndrome.

Authors:  Hsiu-Jen Wang; Wan-Ru Yu; Hueih-Ling Ong; Hann-Chorng Kuo
Journal:  Toxins (Basel)       Date:  2019-11-19       Impact factor: 4.546

Review 4.  Urinary Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome and Its Impact on Therapeutic Outcome.

Authors:  Hung-Yu Lin; Jian-He Lu; Shu-Mien Chuang; Kuang-Shun Chueh; Tai-Jui Juan; Yi-Chang Liu; Yung-Shun Juan
Journal:  Diagnostics (Basel)       Date:  2021-12-29

Review 5.  Management of Bladder Pain Syndrome (BPS): A Practical Guide.

Authors:  Patrick Juliebø-Jones; Karin M Hjelle; Jannike Mohn; Gigja Gudbrandsdottir; Ingunn Roth; Adeel Asghar Chaudhry; Anne Kvåle Bergesen; Christian Beisland
Journal:  Adv Urol       Date:  2022-01-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.